(Z)-7-[(1R,2R,3S,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoate;[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azanium

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-7-[(1R,2R,3S,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoate;[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azanium
• 化学式: C25H47NO8
• 分子量: 489.6
• InChiKey: UMMADZJLZAPZAW-OVXHCKHTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.96
• 重原子数：
  34
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  189
• 氢给体数：
  7
• 氢受体数：
  8

ADMET

代谢

在肺和肝脏中代谢。代谢物通过尿液排出。

Metabolized in the lungs and liver. Metabolites are excreted in urine.

来源:DrugBank

毒理性

• 毒性总结

过量症状包括刺激、恶心、呕吐、腹泻、咳嗽、呼吸困难、哮喘、高血压、潮红和发热。

Symptoms of overdose include irritation, nausea, vomiting, diarrhea, coughing, dyspnea, asthma, hypertension, flushing, and pyrexia.

来源:DrugBank

文献信息

• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• [EN] PROCESS FOR THE PREPARATION OF CARBOPROST AND ITS TROMETHAMINE SALT<br/>[FR] PROCÉDÉ PERMETTANT LA PRÉPARATION DE CARBOPROST ET DE SON SEL DE TROMÉTHAMINE
  申请人：CHINOIN GYÓGYSZER ÉS VEGYÉSZETI TERMÉKEK GYÁRA ZRT

  公开号：WO2017093770A1

  公开（公告）日：2017-06-08

  The subject of the invention is a novel process for the preparation of Carboprost tromethamine salt where alkylation the enone of the general formula (II) is carried out in the presence of a chiral auxiliary in aprotic solvent with a Grignard reagent. The methyl ester epimers of formula (VII) are separated by gravity silicagel chromatography and the salt formation is carried out by using solid tromethamine base.

  本发明的主题是一种制备Carboprost tromethamine盐的新工艺，其中在无极溶剂中使用Grignard试剂，在手性辅助剂的存在下烷基化通式（II）的烯酮。公式（VII）的甲酯外消旋体通过重力硅胶色谱分离，并使用固体tromethamine碱进行盐形成。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• [EN] PREPARATION METHOD FOR AND USES OF CARBOPROST TROMETHAMINE CRYSTAL<br/>[FR] PROCÉDÉ DE SYNTHÈSE ET APPLICATIONS D'UN CRISTAL DE TROMÉTHAMINE DE TYPE CARBOPROST
  申请人：SHANGHAI TECHWELL BIOPHARM CO

  公开号：WO2012010089A1

  公开（公告）日：2012-01-26

  公开了一种如式I所示的卡前列素氨丁三醇的晶体，所述晶体在X射线衍射图谱中，在下述2Θ值处有特征峰：6.6±0.2°、9.9±0.2°、18.5±0.2°和20.1±0.2°。进一步地，公开了上述晶体的制备方法和用途。